Barrenjoey revalued Rokt holdings up 28pc citing earnings surge
Rokt was founded in 2012 and uses artificial intelligence to help companies selling products online optimise what they present to shoppers. It was last valued at $US3.5 billion ($5.3 billion) earlier this year when Barrenjoey, along with Square Peg Capital and Tiger Global Management acquired shares from some of the company's early staff and investors.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mercury
5 hours ago
- Mercury
Doubling up: How ASX biotechs are multiplying their impact
ASX companies finding smarter ways to stretch value of existing assets and launch into broader clinical areas LTR Pharma leveraging proven intranasal platform for erectile dysfunction treatment to target non-invasive relief for patients with swallowing difficulties From concussion to Alzheimer's the CogState Cognigram digital cognitive assessment system is used by physicians to monitor brain function As global biotech faces increasing pressure to deliver more with less, several ASX-listed healthcare companies are working to find smarter ways to stretch the value of their existing assets. Whether it's repurposing a drug delivery platform, extending the reach of a diagnostic tool or developing next-generation compounds that act on the same biological pathway to treat other conditions, these companies are using proven science as a launchpad into broader clinical territory. The strategy is playing out globally, with Novo Nordisk and Eli Lilly providing high-profile examples of repurposing GLP-1 drugs – originally developed for type 2 diabetes – for weight loss. Blockbusters like Ozempic/Wegovy (Novo Nordisk) and Mounjaro/Zepbound (Eli Lilly) are now reshaping treatment for obesity and related conditions. It's a compelling demonstration of how one well-validated mechanism of action can be leveraged across multiple disease areas in turn lowering development risk, tapping into existing safety and efficacy data, and accelerating time to market. For ASX healthcare companies navigating tighter capital conditions, similar strategies are proving to be a smart and resourceful way to unlock broader clinical value from their existing platforms. LTR Pharma rises above ED with nasal spray tech targeting broader conditions Developer of a nasal spray treatment for erectile dysfunction (ED), LTR Pharma (ASX:LTP) has turned to a secondary program using its innovative intranasal delivery platform but this time for oesophageal motility disorders (OMD). In May, LTR Pharma announced it had inked a collaborative development agreement with US-based Strategic Drug Solutions (SDS) to develop Oroflow a spray for OMD – a group of conditions that cause impaired swallowing (dysphagia). The program leverages LTR's proven proprietary intranasal delivery platform and foundational work from its Spontan and Roxus ED treatments to target rapid symptom relief for patients with swallowing difficulties, potentially offering a non-invasive alternative to current treatments. Oroflow aims to deliver relief in 10 minutes, bypassing swallowing barriers and offering a compelling althernative to treatments including invasive procedures such as pneumatic dilation, surgery, or botulinum toxin injections. LTR Pharma is addressing a $4.5 billion OMD market projected to reach $8.1 bn by 2034 with the company announcing in its latest quarterly report that proof-of-concept testing preparations were underway. LTR Pharma executive chairman Lee Rodne said Oroflow represented an exciting expansion of its nasal spray platform. "For patients with swallowing difficulties, oral medications present obvious challenges for patients," he said. "Our nasal spray technology is designed to offer a patient-friendly solution that avoids the need to swallow medications, have surgery or undergo other problematic treatments while providing rapid symptom relief. Neuren targeting broad set of neurological conditions Neuren Pharmaceuticals (ASX:NEU) is another standout. The company and US partner Acadia was in 2023 granted the first US Food and Drug Administration (FDA) approval for a drug to treat Rett syndrome, a rare neurological disorder mostly affecting girls and emerging in infancy. Trofinetide, marketed as Daybue, is a synthetic analog of part of the hormone insulin-like growth factor 1 (IGF-1), which is a potent regulator of central nervous system development. Neuren is now advancing NNZ-2591, which also targets IGF-1. Building on the scientific foundation of trofinetide, NNZ-2591 is structurally optimised to improve brain penetration, enhance tolerability, and expand therapeutic reach across a broader set of neurodevelopmental conditions. Using a strategy that targets multiple indications from one compound, Neuren aims to accelerate development while reducing R&D expenses. Currently in phase II trials, NNZ-2591 could open new treatment avenues for other underserved neurodevelopmental conditions like Phelan-McDermid, Angelman, and Pitt-Hopkins syndromes. The company is preparing to start a phase III study of NNZ-2591 for its most advanced program Phelin McDermid. It also plans to consult with the FDA this year to establish a clinical path for NNZ-2591 to treat hypoxic-ischemic encephalopathy (HIE), which results from a baby's brain not getting enough oxygen or blood flow before, or shortly after, birth. "We believe the mechanism of action of NNZ-2591 can be broadly applicable to neurodevelopmental disorders, independent of the genetic origin," CEO Jon Pilcher told Stockhead. "We are striving to be successful in multiple settings, for the benefit of both the impacted families and our shareholders." Tracking cognition from concussion to Alzheimer's From footy fields to neurology clinics, the CogState (ASX:CGS) Cognigram digital cognitive assessment system is used by physicians to monitor key aspects of brain function – including processing speed, attention, visual learning, working memory and executive function. The test can assess cognition at a single point in time or track changes over multiple assessments. You may have heard of it referred to as the Cogstate concussion test in footy coverage. However, Cognigram has since evolved into a widely used tool in healthcare and research. Cogstate is riding a wave of global demand for cognition-related clinical trials, particularly in the race to treat Alzheimer's disease and related dementias. The company recently upgraded its financial guidance for FY25, reflecting strong performance and improved outlook across key financial metrics. Full-year profit before tax is forecast to be in the range of $12-14m, an improvement of 69% to 97% on FY24. "We are now using Cognigram, which is the same cognitive assessment used to assess AFL footballers for concussion, to prescreen for clinical trials in the earlier stages of Alzheimer's," CEO Brad O'Connor told Stockhead. "We have a contract with a large pharmaceutical company screening for 20,000 patients in the community to find those that might be appropriate to include in their very early stage Alzheimer's trials. At Stockhead, we tell it like it is. While LTR Pharma is a Stockhead advertiser, the company did not sponsor this article. Originally published as Doubling up: How ASX biotechs are multiplying their impact
Herald Sun
6 hours ago
- Herald Sun
Harvest Tech posts 135% revenue growth
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. Harvest Technology Group records 135% YoY increase in quarterly revenue Raises $970,000 through mix of debt and convertible note instruments Dual lists on Frankfurt Stock Exchange to broaden investor base Special Report: Harvest Technology Group has recorded a 135% YoY increase in quarterly revenue, reaching $1.1 million in Q4 FY25, with the company expecting to exceed $3.5 million in total revenue for the full year. Cash receipts for remote communications tech-solutions provider Harvest Technology Group (ASX:HTG) for the June quarter came in at $631,000 with net cash inflows of $127,000. Net operating cash outflows for the quarter totalled $662,000 including $570,000 in R&D, $205,000 in staff, $17,000 in sales and marketing, $371,000 in corporate and administration, $105,000 in interest and $25,000 in other costs. HTG strengthened its balance sheet during the quarter, raising $970,000 (before costs) through a mix of debt and convertible note instruments including: $450,000 in unsecured convertible notes launched on June 30; $130,000 in secured convertible notes launched on June 27; and $390,000 short-term loan from managing director. After quarter end, HTG received a further $530,000 in funding in July through additional convertible notes and another loan from the managing director. In June HTG said it was tracking one year ahead of its pathway-to-profit plan as it focused on achieving a positive EBITDA before July 2026. As of June 30, HTG had $723,000 cash. Listing on Frankfurt Stock Exchange In a significant step toward expanding its international presence, HTG listed its shares on the open market segment of the Frankfurt Stock Exchange in April 2025. The dual listing is expected to broaden the investor base and increase visibility across European capital markets, with the company already experiencing an increase in trading volumes across both exchanges. In other key developments during the June quarter, HTG appointed Hugh Bickerstaff as sales and marketing director and strategic advisor. Bickerstaff brings deep expertise in founding and scaling some of Australia's fastest-growing technology businesses and is an experienced mentor in the sector. Start of Project Neon and new customer wins HTG also started project Neon, an Edge AI-enabled solution aimed at improving real-time decision-making in remote environments. The company secured new customer wins including two subsea services clients, with initial hardware sales and software subscriptions scheduled to begin in Q1 FY26. Additionally, the company expanded deployments across an existing customer fleet, unlocking further hardware sales and an uplift in recurring revenue from software. HTG continued engagement with a European defence customer via its Australian channel partner and began deploying its Nodestream technology across a new uncrewed surface vessel fleet in the Middle East. Enhancements to Nodestream platform In a major product milestone, HTG successfully integrated its Autopilot and Nodestream systems into a single, IP-rated enclosure. The robust weatherproof design simplifies installation and reduces the equipment footprint for deployment on autonomous vehicles and maritime vessels. The company also delivered significant improvements to its Nodestream platform during the quarter including a doubling of available data channels from 10 to 20, enabling more data-intensive operations. Additionally, the user interface has been overhauled to provide a more intuitive and efficient user experience. A comprehensive user permissions framework was introduced in Nodestream Live, improving access control and collaboration across distributed teams. This article was developed in collaboration with Harvest Technology Group, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions. Originally published as Harvest Tech posts 135% quarterly revenue surge
Herald Sun
6 hours ago
- Herald Sun
PEC to drill-test Raptor REE
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. Perpetual plans deeper drilling across Raptor prospects to support maiden JORC resource estimate Program will follow-up on auger drilling that returned high-grades of magnet REE-rich mineralisation Company will also advance detailed metallurgical testwork and mineralogical characterisation Special Report: Perpetual Resources is finalising plans for the next phase of drilling targeting depth extensions at the Portão Verde, Pina Colada and Pinheirinho prospects of its Raptor rare earths project in Brazil. This program will be designed to fully assess broader project-scale potential to support a maiden JORC resource estimate. Perpetual Resources (ASX:PEC) intends for the follow-up aircore holes to be drilled to depths of 30-40m to follow previous shallow auger holes demonstrating that mineralisation is open at depth. This program will assess mineralisation at depth and test its full extent across the project to understand the volume potential. Notable previous assays from the earlier drilling, which was limited by handheld auger capacity, include: 5m grading 5591ppm total rare earth oxides (35% neodymium and praseodymium) ending in 5533ppm TREO; and 12m at 4601ppm TREO (23% NdPr) ending in 2914ppm TREO. Metallurgical testing by ANSTO has also recovered up to 94% for key magnet REEs. Highlights from metallurgical testwork following maiden drilling. Pic: Perpetual Resources Raptor project The Raptor project sits within the world-class Caldeira Alkaline Complex in Minas Gerais, a region that is rapidly emerging as a globally significant hub for ionic adsorption clay-hosted REEs. It is close to Meteoric Resources' (ASX:MEI) Caldeira project, which has a resource of 1.5Bt at 2359ppm TREO and Viridis Mining and Minerals' (ASX: VMM) Colossus project. Both projects have recently attracted substantial government grant funding and institutional equity support – underscoring growing national and global interest in the district's critical minerals potential. PEC's upcoming drill program will investigate new high-priority targets across the broader project area. The company will also advance detailed metallurgical test work and mineralogical characterisation to support future development studies and underpin Raptor's positioning as a potential long-term supplier of critical rare earths. This article was developed in collaboration with Perpetual Resources, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions. Originally published as Perpetual Resources gears up for REE resource drilling at Raptor
